Neurizon Therapeutics Limited (NUZ.AX)
- Previous Close
0.1400 - Open
0.1450 - Bid 0.1350 x --
- Ask 0.1450 x --
- Day's Range
0.1350 - 0.1450 - 52 Week Range
0.0960 - 0.2450 - Volume
188,653 - Avg. Volume
349,823 - Market Cap (intraday)
66.461M - Beta (5Y Monthly) 1.24
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date Jul 28, 2025 - Aug 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.56
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
www.neurizon.comRecent News: NUZ.AX
View MorePerformance Overview: NUZ.AX
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NUZ.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NUZ.AX
View MoreValuation Measures
Market Cap
66.46M
Enterprise Value
64.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.58
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-60.46%
Return on Equity (ttm)
-150.50%
Revenue (ttm)
1.52M
Net Income Avi to Common (ttm)
-14.58M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
10.11M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.73M